The number of IPOs fell sharply with the dot-com bust and ... and winner-take-all effects, Ritter said. Companies that enter and dominate a sector early tend to see increasing returns, while ...

Odyssey Therapeutics is a promising biotech firm poised for IPO success with a focus on inflammatory and autoimmune diseases ...

PARIS - Beauty M&A may be slow Stateside, but global IPO season is about to kick off - again. Initial public offerings were ...

According to a 2020 market research report by Grand ... the company’s enterprise value at IPO would approximate $4.1 billion, excluding the effects of underwriter over-allotment options.

The funds will support the development of Ascentage’s pipeline, including its lead candidate olverembatinib to treat blood ...

Renaissance Capital provides pre-IPO research to institutional investors and investment banks. The Firm manages two IPO-focused funds: The Renaissance IPO ETF (NYSE: IPO) and the Renaissance ...

The provider of oil production-enhancement services saw its share price jump about 24% in its first day of trading.

A global biopharma with a U.S. headquarters in Montgomery County is gearing up to go public on a U.S. exchange.

To judge by the comments from Term Sheet readers who particpated in our survey, the coming year may bring some relief as a new presidential administration and regulatory regime come into effect ...

climbing interest rates and Russia’s invasion of Ukraine helped cast a chilling effect on new issues. Justworks, which was chasing a $2 billion valuation, decided to keep its IPO registration ...